Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.

about

Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule.

Item

http://www.wikidata.org/entity/Q40113613

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Molecular design and downstrea ...... runcated factor VIII molecule.

@en

type

Item

label

Molecular design and downstrea ...... runcated factor VIII molecule.

@en

prefLabel

Molecular design and downstrea ...... runcated factor VIII molecule.

@en

P1476

Molecular design and downstrea ...... runcated factor VIII molecule.

@en

P2093

Ernst B Hansen

http://www.w3.org/2001/XMLSchema#string

Gert Bolt

http://www.w3.org/2001/XMLSchema#string

Haleh Ahmadian

http://www.w3.org/2001/XMLSchema#string

Jens J Hansen

http://www.w3.org/2001/XMLSchema#string

Johan H Faber

http://www.w3.org/2001/XMLSchema#string

Johan Karlsson

http://www.w3.org/2001/XMLSchema#string

Lars Sejergaard

http://www.w3.org/2001/XMLSchema#string

Lars Thim

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of the metal binding sites in a recombinant coagulation factor VIII identifies two sites with unique metal binding properties

Hydrogen exchange mass spectrometry for the analysis of protein dynamics

Structure of human factor VIII

Contact order and ab initio protein structure prediction

Purification and characterization of a new recombinant factor VIII (N8).

Characterization of the polypeptide composition of human factor VIII:C and the nucleotide sequence and expression of the human kidney cDNA.

Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma.

A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity.

CHO cells in biotechnology for production of recombinant proteins: current state and further potential.

Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.

P304

568-575

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MBC.0000000000000477

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26761578

http://www.w3.org/2001/XMLSchema#string

P921

molecular design

P932

4935534

http://www.w3.org/2001/XMLSchema#string